BrightPath Biotherapeutics Co.,Ltd. [4594.T]

TOKYO, May 14 (Pulse News Wire) – Brightpath Biotherapeutics Co., Ltd. (4594.T) reported non-consolidated results for fiscal year 2026 ending March.

Revenue was ¥2.6 billion. operating profit was ¥2,368 million (+90.1%).

Net profit was ¥1,304 million. Total assets stood at ¥2.6 billion with an equity ratio of 90.1%.

Financial results — FY2026/3 (consolidated)

MetricCurrentYoY
Revenue¥0M-92.6%
Operating profit¥-1,295Mn/a
Net profit¥-1,304Mn/a

Next period forecast

Revenue

¥0M

n/a

Op. profit

¥-1,965M

n/a

Net profit

¥-1,949M

n/a

Source: TDNet filing · Figures in millions of yen

Original Disclosure (PDF)

🟢 Confidence: High AI-translated content.